Alan Foreman

Alan is a visionary tech entrepreneur who has built a successful career in the Healthcare Technology industries working with the world’s leading healthcare providers (pharmaceuticals, medical devices, private and public healthcare) and technology providers (software, hardware, platform, cybersecurity, consulting).

As co-founder and CEO of global heart health technology company, B-Secur, Alan has been at the helm of building a world class team, and driving partnerships and commercial success with leading global corporations in US and beyond. B-Secur’s FDA-cleared HeartKey technology is a world’s first which is revolutionising the way people experience technology, bringing personalised and preventative healthcare monitoring to everyone.

Alan leads 70+ experts at B-Secur including world-class scientists, engineers and experienced commercial executives at offices across the U.S., the UK and Ireland, with expanding customer bases in Europe, Americas and Asia. He has also orchestrated unprecedented levels of investment fundraising of any early-stage company in Northern Ireland, including raising investment in U.S., enabling B-Secur to advance a truly unique world's first technology.

Prior to B-Secur, Alan spent almost twenty years at Future Global 500 company, Accenture plc, latterly as Managing Director, working in Products and Healthcare based industries with a strong focus on technology innovation. This involved working with many of the world’s leading technology providers including Microsoft, Apple, IBM, Cisco, EMC and Salesforce.

A prominent member of Northern Ireland’s burgeoning tech sector, Alan works closely with a number of prestigious UK universities including Queen’s University and Ulster University. Alan is a guest lecturer on entrepreneurship at the London School of Economics and works with the Department of Trade and Industry (TDI) and other industry bodies in the UK and Ireland developing strategies for technology leadership. His expert opinion is regularly called upon by international analysts and media in the MedTech industry and he has contributed to articles in Forbes, the BBC, TechCrunch and the Financial Times.